Table 5 Health and economic outcomes (ICERs) of the base case analyses
Liraglutide 1.2 mg | Sitagliptin | Difference | |
|---|---|---|---|
Discounted life expectancy (years) | 14.22 (0.18) | 14.09 (0.17) | 0.13 (0.23) |
Discounted quality-adjusted life expectancy (QALYs) | 9.24 (0.12) | 9.05 (0.11) | 0.19 (0.16) |
Discounted total lifetime direct medical costs (€) | 39524 (1100) | 36727 (1113) | 2797 (1468) |
Drug acquisition | 15069 | 11240 | 3829 |
Patient management* | 1939 | 1928 | 11 |
Cardiovascular disease | 5858 | 6170 | −312 |
Renal disease | 1146 | 1253 | −107 |
Diabetic foot and neuropathy | 6665 | 7132 | −467 |
Eye disease | 5325 | 5676 | −351 |
Hypoglycaemia | 3522 | 3329 | 193 |
ICER (€ per QALY gained) | 15101 | ||
Liraglutide 1.8 mg | Exenatide BID | Difference | |
Discounted life expectancy (years) | 14.10 (0.17) | 13.96 (0.16) | 0.14 (0.23) |
Discounted quality-adjusted life expectancy (QALYs) | 9.22 (0.12) | 9.03 (0.11) | 0.19 (0.16) |
Discounted total lifetime direct medical costs (€) | 43236 (1049) | 41934 (1065) | 1302 (1492) |
Drug acquisition | 18505 | 14927 | 3578 |
Patient management* | 1931 | 1920 | 11 |
Cardiovascular disease | 5544 | 5980 | −436 |
Renal disease | 1611 | 1692 | −81 |
Diabetic foot and neuropathy | 5859 | 6317 | −458 |
Eye disease | 4461 | 4948 | −487 |
Hypoglycaemia | 5326 | 6149 | −823 |
ICER (€ per QALY gained) | 6818 |